Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

An Emerging Model for Pharma
GSK has more than 25 products in its pipeline, a third of which are for diseases that are serious problems in the developing world, says Myers. One is a malaria vaccine, which completed phase II proof-of-concept trials in Mozambique in October 2004. The company is doing trials to see how well it works when administered with other vaccines to children younger than one, who are most susceptible. GSK hopes to enter the critical phase III trials at the end of 2006 or beginning of 2007, which if successful would put the vaccine in the developing world in 2009 at the earliest. The company can’t say for sure what the strategy for introducing the malaria vaccine will be, however, because it is developing the vaccine with partners.

Still, Myers expects the Rotarix experience to be repeated at GSK: “We’ve made it clear that this strategy is not just a one-off.” That could be good news for poor countries. The traditional model of developing a drug or vaccine and recouping costs in the developed world before introducing it farther afield leaves most of the world’s population in peril. Myers expects other companies to follow GSK’s lead in introducing vaccines and drugs quickly to neglected areas. “It’s something that’s going to be needed, and we need to figure out the issues and hurdles that need to be overcome in order to get vaccines as quickly as possible to the people that need them,” she says.

0 comments about this story. Start the discussion »

Tagged: Business

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me